April 25th 2024
With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
RENOTORCH Study of Toripalimab and Axitinib Meets Primary End Point in RCC
April 28th 2023The prespecified interim analysis of the RENOTORCH study showed toripalimab plus axitinib improved progression-free survival, overall response rates, and showed no new safety signals among patients with renal cell carcinoma.
Read More
Oncology Nurses Discuss Adverse Event Management in mRCC Treatment
April 22nd 2023During a live virtual event, Sarah Yenser Wood, RN, MSN, ANP, AOCNP, and a panel of oncology nurses discussed their approaches to management of patients receiving first-line regimens for advanced or metastatic renal cell carcinoma.
Read More
Adjuvant Nivolumab/Ipilimumab Not Recommended for Localized RCC With High-Risk Features
April 20th 2023The phase 3 CheckMate 914 study has missed its primary end point, and the lack of efficacy of nivolumab plus ipilimumab over placebo in the study has led investigators to refer oncologists back to the standard of care, pembrolizumab, as seen in KEYNOTE-564.
Read More
Doublet and Triplet Combinations Continue to Challenge Monotherapy in Advanced RCC
April 6th 2023In an interview with Targeted Oncology™, Yousef Zakharia, MD discussed evidence supporting both doublet and triplet therapy for the treatment of previously untreated, advanced/metastatic renal cell carcinoma.
Read More
Selecting IO/TKI Therapy for mRCC Based on Patient Profile
April 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants their impressions of tyrosine kinase inhibitor plus immune checkpoint inhibitor trials for patients with metastatic renal cell carcinoma.
Read More
Mitigating Toxicities Arising From Combination Therapies in RCC
March 29th 2023Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.
Read More
Campbell Discusses Choices for Patients With Favorable- and Intermediate-Risk RCC
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.
Read More
Roundtable Discussion: Voss Looks at Integrating New Approaches in Clear Cell RCC Treatment
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.
Read More